Business context and reporting period
Inogen, Inc. develops, manufactures and sells or rents portable and stationary oxygen concentrators. This Form 10-K covers the fiscal year ended December 31, 2014; quarterly figures below provide additional Q4 context. Unless stated otherwise, financial amounts are in millions of dollars.
The company’s direct-to-consumer U.S. model combines product marketing, patient support and reimbursement billing. In 2014, 22% of revenue came from international markets and 35% from rentals. The filing was signed April 27, 2015, after a delay related to an audit committee investigation.
Financial results and key metrics
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $112.5 | $75.4 |
| Sales revenue | $73.1 | $44.9 |
| Rental revenue | $39.4 | $30.5 |
| Gross profit / gross margin | $55.5 / 49.3% | $39.0 / 51.7% |
| Operating income | $10.5 | $4.5 |
| Net income | $6.8 | $25.4 |
| Operating cash flow | $15.7 | $13.5 |
| Cash and cash equivalents at year-end | $56.8 | $13.5 |
Revenue increased 49.2% year over year, with sales up 62.8% and rentals up 29.2%. Sales gross margin improved to 47.1% from 45.9%, while rental gross margin declined to 53.5% from 60.2%, primarily reflecting lower reimbursement rates. Overall gross margin fell 2.4 percentage points.
FY 2013 net income included a $21.6 million income tax benefit, largely associated with releasing a deferred-tax valuation allowance. On a company-defined non-GAAP basis, adjusted net income was $6.6 million in 2014 versus $3.6 million in 2013; adjusted EBITDA was $24.0 million versus $13.4 million. These measures are not substitutes for GAAP results.
In Q4 2014, revenue was $29.1 million, gross profit was $13.8 million and net income was $1.5 million. Q4 2013 revenue was $19.8 million, gross profit $10.2 million and net income $22.0 million; the prior-year quarter included a substantial tax benefit. The company reported that the investigation-related Q4 adjustment reduced revenue by $0.3 million and net income by $0.1 million.
Investing activities used $16.3 million in 2014, including $14.5 million for rental equipment. Year-end working capital was $73.8 million. Total indebtedness was $0.6 million, primarily a patent-related obligation; the $15 million JPMorgan revolving facility was undrawn. The company reported compliance with its credit covenants and stated that available liquidity and expected cash generation should cover requirements for at least 12 months.
Material changes versus the prior comparable period
- Revenue growth reflected higher system sales and an increase in rental patients to more than 28,400 from about 21,300. Systems sold increased to about 33,200 from 19,200.
- Operating income rose to $10.5 million from $4.5 million, while reported net income fell because 2013 included the large deferred-tax benefit.
- Operating expenses increased, including sales and marketing expense to $24.1 million from $18.4 million and general and administrative expense to $17.9 million from $13.8 million.
- Cash increased following the February 2014 IPO, which generated approximately $52.5 million in net proceeds before offering expenses. Preferred stock converted to common stock in connection with the IPO.
Outlook, risks, contingencies and unusual items
- Reimbursement: Management estimated that CMS pricing changes for areas not subject to competitive bidding could reduce 2016 revenue by approximately 3–4%. Competitive-bidding prices were materially below standard Medicare allowables; reimbursement and rental caps remain key business risks.
- Product development: The company expected to commercialize a smaller, lighter, lower-cost fourth-generation portable concentrator in 2016. It planned continued investment in sales channels, product development and private-payor contracting.
- Investigation and controls: The audit committee found that five direct-to-consumer sales representatives falsified or improperly modified order documentation and circumvented order-entry procedures. They were terminated; the investigation found no senior-executive involvement or broader systemic falsification. The company reduced Q4 revenue by $0.3 million, with substantially all expected to be recognized after documentation was corrected in 2015. It expected $1.0–$1.5 million of related investigation costs, primarily in Q1 2015.
- Material weakness: Management concluded that disclosure controls and internal control over financial reporting were ineffective at year-end due to inadequate review and monitoring of documentation supporting direct-to-consumer sales and rentals. Remediation was underway; completion was not assured. The external auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- Litigation and filing status: Two securities class actions filed in March 2015 allege misleading financial statements and internal-control disclosures; the company said outcome and potential loss could not be estimated. The Inova Labs patent litigation remained stayed pending patent reexamination. Nasdaq notified the company of noncompliance due to the late 10-K; it had 60 days to submit a compliance plan, and the late filing restricted use of Form S-3 for 12 months.
- Other risks: Medicare and private-payor concentration, claim audits and collection delays, single-source components, competition, product liability, regulatory compliance and foreign-exchange exposure may affect results. Accounts receivable aged over 365 days rose to 16% from 4%, and earned-but-unbilled receivables increased to $3.7 million from $1.4 million.
Important facts for investors to verify
- Progress and independent validation of remediation for the revenue-documentation material weakness, including whether further adjustments or restatements are required.
- Whether corrected Q4 documentation supports recognition of the deferred $0.3 million revenue and how 2015 investigation and litigation expenses develop.
- Cash collection, aging and reserve adequacy for receivables, particularly balances over 365 days and unbilled amounts.
- Actual effects of Medicare competitive bidding, capped rentals and private-payor reimbursement on rental growth and gross margins.
- Commercialization timing and economics of the planned fourth-generation concentrator, and the company’s capacity to fund rental-asset investment while sustaining cash generation.